PTC Therapeutics PTCT
$56.42 −$1.91 (-3.27%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $56.99 +1.01%
Open$58.78
Prev close$58.33
Day range$56.18 – $58.96
Volume952.6K
Market cap$4.71B
P/E (TTM)–
Dividend yield–
PTCT Stock News
Headlines matching PTC Therapeutics or the PTCT ticker, most recent first.
- Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $137 Positive
- Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $109
- Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120
- TD Cowen Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $90
- PTC Therapeutics, Inc.: To Assume Certain Specified Liabilities of Sangamo PTCT
- PTC Therapeutics, Inc.: Upfront Payment of $111 Million, Plus Up to an Additional $100 Million in Contingent Milestone Payments PTCT
- Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $122 Positive
- Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $130
- Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $109 Positive
- BofA Securities Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $96
- Goldman Sachs Maintains PTC Therapeutics(PTCT.US) With Sell Rating, Raises Target Price to $70 Positive
- A Quick Look at Today's Ratings for PTC Therapeutics(PTCT.US), With a Forecast Between $90 to $106
- Wells Fargo Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $106
- Morgan Stanley Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $104 Positive
- RBC Capital Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Raises Target Price to $85 Positive
No comments yet — be the first to weigh in on PTCT.
Sign in to join the discussion.